TROD Medical

TROD Medical is a medical device company. Founded in 2006 by Dr. Andre Faure, the company has significant expertise in developing innovative ablation technologies, particularly radiofrequency ablation devices. TROD Medical has developed a disruptive percutaneous radiofrequency device, EncageTM, capable of ablating tissue with precision unmatched by competitors. This technology represents a major breakthrough in treatments where collateral tissue damage is a significant burden for patients, such as in prostate cancer. Prostate cancer is one of the most common cancers, with approximately 240,000 new cases annually in the United States alone, and it is well-known that its commonly used treatments cannot avoid significant side effects such as erectile dysfunction (impotence) and urinary incontinence.